NCT03907241View on ClinicalTrials.gov

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

September 5, 2019

Study Completion Date

September 5, 2019

Conditions
Primary Immunodeficiency
Interventions
DRUG

Octanorm 16.5%

Human normal immunoglobulin

Trial Locations (7)

43617

Octapharma Research Site, Toledo

68046

Octapharma Research Site, Papillion

75034

Octapharma Research Site, Frisco

80112

Octapharma Research Site, Centennial

92123

Octapharma Research Site, San Diego

92697

Octapharma Research Site, Irvine

T6G2V2

Octapharma Research Site, Edmonton

Sponsors

Lead Sponsor

Octapharma
All Listed Sponsors
lead

Octapharma

INDUSTRY